RU2014127714A - ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile - Google Patents
ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile Download PDFInfo
- Publication number
- RU2014127714A RU2014127714A RU2014127714A RU2014127714A RU2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- seq
- toxa
- toxb
- immunogenic composition
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 7
- 229960005486 vaccine Drugs 0.000 title claims 8
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 98
- 102000036639 antigens Human genes 0.000 claims abstract 98
- 108091007433 antigens Proteins 0.000 claims abstract 98
- 239000000203 mixture Substances 0.000 claims abstract 30
- 230000002163 immunogen Effects 0.000 claims abstract 21
- 229920001184 polypeptide Polymers 0.000 claims abstract 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 150000001413 amino acids Chemical class 0.000 claims abstract 7
- 239000012634 fragment Substances 0.000 claims abstract 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 239000013256 coordination polymer Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- 101710182223 Toxin B Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201121149A GB201121149D0 (en) | 2011-12-08 | 2011-12-08 | Clostridium difficile toxin-based vaccine |
| GB1121149.7 | 2011-12-08 | ||
| GB1217321.7 | 2012-09-27 | ||
| GBGB1217321.7A GB201217321D0 (en) | 2012-09-27 | 2012-09-27 | Vaccine |
| PCT/IB2012/002955 WO2013084071A2 (en) | 2011-12-08 | 2012-12-07 | Clostridium difficile toxin-based vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014127714A true RU2014127714A (ru) | 2016-01-27 |
Family
ID=47747684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014127714A RU2014127714A (ru) | 2011-12-08 | 2012-12-07 | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9694063B2 (enExample) |
| EP (1) | EP2788022B1 (enExample) |
| JP (1) | JP6084631B2 (enExample) |
| KR (1) | KR20140101835A (enExample) |
| CN (1) | CN103974718A (enExample) |
| AU (1) | AU2012349753A1 (enExample) |
| BR (1) | BR112014013876A2 (enExample) |
| CA (1) | CA2858519A1 (enExample) |
| ES (1) | ES2704069T3 (enExample) |
| IL (1) | IL232957A0 (enExample) |
| IN (1) | IN2014CN04071A (enExample) |
| MX (1) | MX2014006630A (enExample) |
| RU (1) | RU2014127714A (enExample) |
| SG (1) | SG11201402375VA (enExample) |
| WO (1) | WO2013084071A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2781057C2 (ru) * | 2017-03-15 | 2022-10-04 | Новавакс, Инк. | Способы и композиции для индукции иммунного ответа против clostridium difficile |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5917682B2 (ja) | 2011-04-22 | 2016-05-18 | ワイス・エルエルシー | 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法 |
| AU2013319821A1 (en) | 2012-09-19 | 2015-02-26 | Novartis Ag | Clostridium difficile polypeptides as vaccine |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014197651A1 (en) * | 2013-06-05 | 2014-12-11 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| KR102395498B1 (ko) * | 2014-01-06 | 2022-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
| CA2952118A1 (en) * | 2014-06-25 | 2015-12-30 | Glaxosmithkline Biologicals S.A. | Clostridium difficile immunogenic composition |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10668140B2 (en) | 2017-02-24 | 2020-06-02 | University Of South Floirida | Non-toxigenic Clostridium difficile spores for use in oral vaccination |
| US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| JP7637988B2 (ja) * | 2019-05-21 | 2025-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クロストリジウム・ディフィシルのワクチン組成物 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| KR920703114A (ko) | 1989-07-14 | 1992-12-17 | 원본미기재 | 접합체 백신을 위한 시토킨 및 호르몬 운반체 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| ATE156710T1 (de) | 1992-06-25 | 1997-08-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| NZ312502A (en) | 1995-07-07 | 1999-03-29 | Oravax Inc | Clostridium difficile toxins as mucosal adjuvants |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| EP1105153A4 (en) | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
| CA2283557A1 (en) | 1997-03-10 | 1998-09-17 | Heather L. Davis | Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1000155A1 (en) | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| WO1999040936A2 (en) | 1998-02-12 | 1999-08-19 | American Cyanamid Company | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| AU746163B2 (en) | 1998-04-09 | 2002-04-18 | Smithkline Beecham Biologicals (Sa) | Adjuvant compositions |
| US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| DE60043930D1 (de) | 1999-03-19 | 2010-04-15 | Glaxosmithkline Biolog Sa | Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| WO2001085748A2 (en) * | 2000-05-10 | 2001-11-15 | Glycodesign Inc. | Designing modulators for glycosyltransferases |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| US20040107461A1 (en) * | 2001-03-30 | 2004-06-03 | Padma Commuri | Glucan chain length domains |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| EP2196217A1 (en) | 2001-09-14 | 2010-06-16 | Cytos Biotechnology AG | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| WO2004041857A2 (en) | 2002-06-17 | 2004-05-21 | Ballard Jimmy D | Mutant of clostridium difficile toxin b and methods of use |
| US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| NZ580828A (en) | 2004-02-06 | 2011-09-30 | Univ Massachusetts | Antibodies against clostridium difficile toxin B and uses thereof |
| EP1833510A4 (en) | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
| US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
| CN101500581B (zh) | 2006-06-08 | 2013-10-30 | 科内尔研究基金会 | 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法 |
| CA2659684A1 (en) | 2006-08-02 | 2008-02-07 | Johannes Gutenberg-Universitaet Mainz | Medicament for lct poisoning |
| CA2693958A1 (en) * | 2007-06-14 | 2008-12-18 | Emergent Biosolutions, Inc. | Chemically modified peptides with improved immunogenicity |
| US8524444B2 (en) * | 2007-06-15 | 2013-09-03 | President And Fellows Of Harvard College | Methods and compositions for detections and modulating O-glycosylation |
| CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| CA2752815A1 (en) | 2009-02-20 | 2010-08-26 | Health Protection Agency | Antibodies to clostridium difficile toxins |
| JP2013503198A (ja) * | 2009-08-27 | 2013-01-31 | シナプティック リサーチ，リミテッド ライアビリティ カンパニー | 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系 |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| WO2011063346A1 (en) | 2009-11-20 | 2011-05-26 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment |
| EP2519257A4 (en) * | 2009-12-02 | 2014-10-15 | Univ Tufts | ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| MX343356B (es) | 2010-03-30 | 2016-11-03 | Pfenex Inc * | Toxinas proteicas recombinantes de alto nivel de expresion. |
| AU2011239470B2 (en) * | 2010-04-15 | 2015-09-10 | Progenics Pharmaceuticals, Inc. | Antibodies for the treatment of Clostridium difficile-associated infection and disease |
| SI2753352T2 (sl) | 2010-09-03 | 2022-10-28 | Valneva Austria Gmbh | Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba |
| US8431361B2 (en) | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| WO2012118693A1 (en) | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
| JP5917682B2 (ja) * | 2011-04-22 | 2016-05-18 | ワイス・エルエルシー | 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法 |
| PL3138916T3 (pl) | 2011-05-27 | 2019-11-29 | Glaxosmithkline Biologicals Sa | Kompozycja immunogenna |
| AR087716A1 (es) * | 2011-08-31 | 2014-04-09 | Valent Biosciences Corp | Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2012
- 2012-12-07 IN IN4071CHN2014 patent/IN2014CN04071A/en unknown
- 2012-12-07 AU AU2012349753A patent/AU2012349753A1/en not_active Abandoned
- 2012-12-07 CA CA2858519A patent/CA2858519A1/en not_active Abandoned
- 2012-12-07 BR BR112014013876A patent/BR112014013876A2/pt not_active IP Right Cessation
- 2012-12-07 SG SG11201402375VA patent/SG11201402375VA/en unknown
- 2012-12-07 CN CN201280060487.1A patent/CN103974718A/zh active Pending
- 2012-12-07 US US14/363,387 patent/US9694063B2/en active Active
- 2012-12-07 WO PCT/IB2012/002955 patent/WO2013084071A2/en not_active Ceased
- 2012-12-07 KR KR1020147018480A patent/KR20140101835A/ko not_active Withdrawn
- 2012-12-07 EP EP12826538.6A patent/EP2788022B1/en active Active
- 2012-12-07 RU RU2014127714A patent/RU2014127714A/ru not_active Application Discontinuation
- 2012-12-07 MX MX2014006630A patent/MX2014006630A/es unknown
- 2012-12-07 JP JP2014545387A patent/JP6084631B2/ja active Active
- 2012-12-07 ES ES12826538T patent/ES2704069T3/es active Active
-
2014
- 2014-06-05 IL IL232957A patent/IL232957A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2781057C2 (ru) * | 2017-03-15 | 2022-10-04 | Новавакс, Инк. | Способы и композиции для индукции иммунного ответа против clostridium difficile |
| RU2781057C9 (ru) * | 2017-03-15 | 2022-11-10 | Новавакс, Инк. | Способы и композиции для индукции иммунного ответа против clostridium difficile |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015500827A (ja) | 2015-01-08 |
| AU2012349753A1 (en) | 2014-06-19 |
| EP2788022B1 (en) | 2018-10-31 |
| IL232957A0 (en) | 2014-07-31 |
| SG11201402375VA (en) | 2014-10-30 |
| JP6084631B2 (ja) | 2017-02-22 |
| WO2013084071A3 (en) | 2013-11-07 |
| EP2788022A2 (en) | 2014-10-15 |
| WO2013084071A2 (en) | 2013-06-13 |
| BR112014013876A2 (pt) | 2019-09-24 |
| CN103974718A (zh) | 2014-08-06 |
| US9694063B2 (en) | 2017-07-04 |
| ES2704069T3 (es) | 2019-03-14 |
| KR20140101835A (ko) | 2014-08-20 |
| IN2014CN04071A (enExample) | 2015-10-23 |
| US20150132333A1 (en) | 2015-05-14 |
| MX2014006630A (es) | 2014-07-09 |
| CA2858519A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
| RU2016111934A (ru) | Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы | |
| JP2011250797A5 (enExample) | ||
| NO20071609L (no) | Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker | |
| JP2012523246A5 (enExample) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| UA110806C2 (uk) | Мікобактеріальна антигенна композиція | |
| MA32819B1 (fr) | Vaccin combine notamment contre la coqueluche acellulaire | |
| JP2015500827A5 (enExample) | ||
| EP4226938A3 (en) | Coronavirus vaccine | |
| AU2017272265B2 (en) | Enhancing immunity to tuberculosis | |
| SI2714910T1 (en) | An immunogenic composition | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| UA110024C2 (uk) | Вакцинний вектор і спосіб посилення імунної відповіді | |
| JP2016504993A5 (enExample) | ||
| RU2015107435A (ru) | Композиции и способы для лечения активной инфекции mycobacterium tuberculosis | |
| JP2015529677A5 (enExample) | ||
| Sánchez et al. | Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection | |
| Garg et al. | Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain | |
| RU2015100889A (ru) | Вакцины для менингококка серогруппы х | |
| EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170515 |